Merrimack Pharmaceuticals, Inc.

Merrimack Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Merrimack Pharmaceuticals, Inc. is not very popular among insiders. Merrimack Pharmaceuticals, Inc. is a mediocre stock to choose.
Log in to see more information.
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in disc...
MACK Fundamental Data by TradingView

News

MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024
MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nMerrimack Pharmaceuticals just reported results for the first quarter of 2024.\nThe post MACK Stock Earnings: Merrimack Pharmaceuticals...\n more…

Merrimack Pharmaceuticals stockholders approve plan of dissolution
Merrimack Pharmaceuticals stockholders approve plan of dissolution

Seeking Alpha - Healthcare Merrimack Pharmaceuticals stockholders approve plan of dissolution...\n more…

Merrimack Pharmaceuticals Approves Liquidation and Dividend
Merrimack Pharmaceuticals Approves Liquidation and Dividend

TipRanks Financial Blog Merrimack Pharmaceuticals Inc. (MACK) just unveiled an announcement. Merrimack Pharmaceuticals, Inc. stockholders have overwhelmingly voted to approve the company's...\n more…

Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

Business Wire Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (Merrimack or the Company) announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution...\n more…

Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution

Business Wire Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (Merrimack or the Company) today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share...\n more…

Strs Ohio Purchases New Stake in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)
Strs Ohio Purchases New Stake in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)

Zolmax Strs Ohio bought a new stake in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission...\n more…